Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Networking & Security
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Cleveland State University manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The university currently has 4 pending office actions, which are assigned to 4 distinct examiners. This ratio between actions and examiners indicates that the university's current applications are being reviewed independently by multiple individuals at the patent office.
The prosecution activity is distributed across 4 distinct art units, reflecting a wide range of technical research within the Biotechnology & Pharmaceuticals sector. DICKINSON, PAUL W is the busiest examiner for the portfolio, currently handling 1 busiest examiner pending office action. With 4 pending office actions spread across different art units, the university faces a complex prosecution landscape that requires navigating various examiner expectations. For a practitioner, this distribution means that the outcome of one office action is unlikely to influence the others, as each is being handled in a unique administrative and technical environment. The university's current profile suggests a diverse array of intellectual property assets that span multiple specialized fields of study.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 1 | 63.1% | +9.5% |
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
| THROWER, LARRY W | 1 | 65.9% | +12.6% |
| ALMEIDA, DEVIN E | 1 | 71.5% | +11.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17326796 | PRIVACY PRESERVING APPROACH TO PEAK LOAD MANAGEMENT | ALMEIDA, DEVIN E | 23d |
| 18235920 | TUMOR RESECTION PROCESS AND COMPOSITION CONTAINING IRIDIUM-CONTAINING NUCLEOSIDE | DICKINSON, PAUL W | — |
| 17706997 | INFECTION-RESISTANT AND BIOACTIVE INTERBODY DEVICE, AND ASSOCIATED COMPOSTION AND METHOD | THROWER, LARRY W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17326796 | PRIVACY PRESERVING APPROACH TO PEAK LOAD MANAGEMENT | ALMEIDA, DEVIN E | 23d |
| 17987058 | COMPOSITIONS AND METHODS OF TREATMENT OF SICKLE CELL ANEMIA AND BETA-THALASSEMIA | HALVORSON, MARK | — |
| 17706997 | INFECTION-RESISTANT AND BIOACTIVE INTERBODY DEVICE, AND ASSOCIATED COMPOSTION AND METHOD | THROWER, LARRY W | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1646 | 1 |
| 1754 | 1 |
| 2492 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18235920 | TUMOR RESECTION PROCESS AND COMPOSITION CONTAINING IRIDIUM-CONTAINING NUCLEOSIDE | DICKINSON, PAUL W | 1618 | §103§112 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 17987058 | COMPOSITIONS AND METHODS OF TREATMENT OF SICKLE CELL ANEMIA AND BETA-THALASSEMIA | HALVORSON, MARK | 1646 | §112 | Non-Final OA | — | Pending | Nov 15, 2022 |
| 17706997 | INFECTION-RESISTANT AND BIOACTIVE INTERBODY DEVICE, AND ASSOCIATED COMPOSTION AND METHOD | THROWER, LARRY W | 1754 | §102§103 | Final Rejection | — | Pending | Mar 29, 2022 |
| 17326796 | PRIVACY PRESERVING APPROACH TO PEAK LOAD MANAGEMENT | ALMEIDA, DEVIN E | 2492 | §102§103 | Final Rejection | 23d | Pending | May 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial